ArticleCells2022
Increased Numbers of Enteric Glial Cells in the Peyer's Patches and Enhanced Intestinal Permeability by Glial Cell Mediators in Patients with Ileal Crohn's Disease.
Article in Cells, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 26 citations in OpenAlex.
- A model for Crohn's disease post-ileal resection fibrosis development using human ileal enteroids and myofibroblasts.Frontiers in physiology · 2026Article
- Enteric nervous system as a therapeutic target in gastrointestinal disorders.World journal of gastrointestinal pharmacology and therapeutics · 2025Article
- The Duodenal Microenvironment in Functional Dyspepsia.Journal of neurogastroenterology and motility · 2025Review
- The mesenteric adipokine SFRP5 alleviated intestinal epithelial apoptosis improving barrier dysfunction in Crohn's disease.iScience · 2024Article
- Elevated risk of adverse effects from foodborne contaminants and drugs in inflammatory bowel disease: a review.Archives of toxicology · 2024Review
- Enteric Nervous System Alterations in Inflammatory Bowel Disease: Perspectives and Implications.Gastrointestinal disorders (Basel, Switzerland) · 2024Article
- Intestinal Membrane Function in Inflammatory Bowel Disease.Pharmaceutics · 2023Review
- β-adrenergic signaling triggers enteric glial reactivity and acute enteric gliosis during surgery.Journal of neuroinflammation · 2023Article
- Mini-review: Enteric glial cell reactions to inflammation and potential therapeutic implications for GI diseases, motility disorders, and abdominal pain.Neuroscience letters · 2023Article
- Crohn's disease: Why the ileum?World journal of gastroenterology · 2023Review
- Guardians of the gut: influence of the enteric nervous system on the intestinal epithelial barrier.Frontiers in medicine · 2023Review
- Neuroimmune regulation in Hirschsprung's disease associated enterocolitis.Frontiers in immunology · 2023Review
- Neonatal development of intestinal neuroimmune interactions.Trends in neurosciences · 2022Review
- Enteric Glial Cells in Immunological Disorders of the Gut.Frontiers in cellular neuroscience · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
Abstract
Enteric glial cells (EGC) are known to regulate gastrointestinal functions; however, their role in Crohn's disease (CD) is elusive. Microscopic erosions over the ileal Peyer's patches are early signs of CD. The aim of this work was to assess the localization of EGC in the follicle and interfollicular region of the Peyer's patches and in the lamina propria and study the effects of EGC mediators on barrier function in CD patients and non-inflammatory bowel disease (non-IBD) controls. EGC markers, glial fibrillary acidic protein (GFAP), and S100 calcium-binding protein β (S100β) were quantified by immunofluorescence and Western blotting. Both markers showed significantly more EGC in the Peyer's patches and lamina propria of CD patients compared to the non-IBD controls. In CD patients there were significantly more EGC in Peyer's patches compared to lamina propria, while the opposite pattern was seen in controls. Barrier function studies using Ussing chambers showed increased paracellular permeability by EGC mediators in CD patients, whereas permeability decreased by the mediators in controls. We show the accumulation of EGC in Peyer's patches of CD patients. Moreover, EGC mediators induced barrier dysfunction in CD patients. Thus, EGC might have harmful impacts on ongoing inflammation and contribute to the pathophysiology of the disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.